Pharmabiz
 

Debiopharm begins phase I/II trial of HSP90 Inhibitor Debio 0932

Lexington, MassachusettsThursday, August 16, 2012, 17:00 Hrs  [IST]

Curis, Inc., a drug development company seeking to develop proprietary targeted medicines for cancer treatment, announced that Swiss-based Debiopharm Group, a global biopharmaceutical group of companies, has started treating patients in its HALO phase I/II clinical trial of orally-administered Heat Shock Protein 90 (HSP90) inhibitor Debio 0932 in combination with chemotherapy regimens in patients with advanced stages of non-small cell lung cancer (NSCLC).

“Our team is pleased to report that we have successfully advanced Debio 0932 into a large clinical trial to study its potential to provide benefit to patients suffering from non-small cell lung cancer,” said Rolland-Yves Mauvernay, president and founder of Debiopharm Group, who added: "We believe that HSP90 represents an important molecular target in cancer therapy in general and in lung cancer in particular. We expect this phase I-II study as well as the ongoing phase I b clinical trial to yield key data that will guide this important molecule's further development."

"Debiopharm has generated a body of clinical data with Debio 0932 to date, showing that it is generally well tolerated and that the molecule demonstrates signs of clinical activity, including a confirmed partial response that was observed in a patient with K-ras-mutated lung cancer," said Dan Passeri, Curis' president and chief executive officer. "We believe that these data demonstrate the potential of Debio 0932 and our HSP90 inhibitor technology, and importantly, Curis is eligible for future milestone payments based on the successful achievement of specific clinical development and regulatory approval objectives under this collaboration."

The HALO (HSP90 inhibition And Lung cancer Outcomes) study is a phase I-II clinical trial of the safety and efficacy of the oral HSP90 inhibitor Debio 0932 in combination with standard of care (SOC) agents in first- and second-line therapy of patients with advanced NSCLC.

On August 10, 2012, Debiopharm initiated the phase I portion of this clinical trial designed to determine the recommended phase II dose of Debio 0932 in combination with various chemotherapy regimens in patients with stage IIIb or IV NSCLC with disease that is characterized as wild-type EGFR (Epidermal Growth Factor). Debio 0932 will be administered in this study in combination with cisplatin/pemetrexed and cisplatin/gemcitabine in treatment-naïve patients, and with docetaxel in previously treated patients.

Once a recommended phase II dose of Debio 0932 in combination with each of the three chemotherapy regimens described above has been identified, the randomized, double-blind, placebo-controlled phase II portion of this study will then begin where approximately 140 eligible patients will be randomized to receive chemotherapy with either placebo or Debio 0932. The primary objective of the phase II study is to determine the efficacy of Debio 0932 in combination with chemotherapy. The KRAS mutation status will also be assessed and used as a stratification factor.

HSP90 is a chaperone protein that controls the folding and processing of certain client proteins. HSP90 clients include many proteins that drive tumor development and progression, such as EGFR, HER2, c-MET, AKT, KIT, FLT3, and VEGFR. Inhibition of HSP90 leads to degradation of client proteins targeting multiple oncogenic signaling pathways.

Debio 0932 is an oral second-generation HSP90 inhibitor, which has shown extended tumor retention, blood-brain-barrier penetration, and promising anti-tumor activity both as monotherapy and in combination against a broad range of tumors in pre-clinical models.

Debiopharm presented data from the dose escalation portion of an ongoing phase I clinical trial study at the annual meeting of the American Society of Clinical Oncology in June 2012. Debio 0932 was generally well tolerated in this study and showed promising signs of anti-tumour activity in patients with advanced solid tumours, especially lung cancer. The objectives of this ongoing phase Ib portion of the study are to further assess the safety profile, pharmacokinetics and pharmacodynamics of Debio 0932, and to make a preliminary assessment of anti-tumour activity in patients with advanced solid tumours, including patients with NSCLC.

In preclinical testing Debio 0932 demonstrated potent anti-proliferative activity against a broad range of cancer cell lines, including many NSCLC cell lines which are resistant to SOC agents. Debio 0932 potently inhibits tumour growth in subcutaneous xenograft models of a number of solid and haematological malignancies, including models of NSCLC which harbor mutations conferring acquired or primary erlotinib resistance. Furthermore, Debio 0932 is able to extend animal survival in models of brain metastasis due to its ability to cross the blood-brain barrier, and it enhances the activity of several SOC agents in animal models of cancer.

Debiopharm Group (Debiopharm) is focussed on the development of prescription drugs that target unmet medical needs.

 
[Close]